Ivermectin does NOT stop Covid patients from becoming severely ill, trial reveals
Ivermectin does not prevent Covid patients from becoming severely ill, scientists have found.
The drug, used to treat head lice and scabies, has had a tumultuous history during the pandemic. It has been touted as a miracle remedy because numerous studies have suggested it can beat the virus. But experts have criticised the experiments of the medication, which costs pennies, as being deeply flawed and unreliable and insist there's not enough evidence to say it has any benefit.
Now researchers in Malaysia have concluded ivermectin is ineffective at preventing hospitalised patients from becoming severely ill.
Medics from Raja Permaisuri Bainun Hospital analysed data from a randomised trial of ivermectin among 490 Covid patients between May and October 2021.
The patients were classified as suffering from mild to moderate levels of illness as a result of Covid, and about half were given the drug in an attempt to test if it helped them from becoming severely ill.
All patients were over the age of 50 and had comorbidities that made them more at risk from severe Covid infection.
Severe disease developed in 21.6 per cent of patients given ivermectin and in 17.3 per cent of those who received only standard care, the researchers said.

The researchers said their findings do not support the use of ivermectin for patients with Covid

Ivermectin as a Covid treatment has been championed by vaccine sceptic figures such as Laurence Fox, who pictured here used it when he was infected by Covid earlier this year. Mr Fox said he picked up a supply of the drug while on holiday in Mexico, where it is available 'over the counter'
They defined severe disease as requiring oxygen to help with breathing.
There were no statistically significant differences between the groups in rates of ICU admission, need for mechanical ventilation, or death, according to the study.
The researchers concluded that their findings do not support the use of ivermectin for patients with Covid.
However, both doctors and patients knew which group the patients had been assigned to, and this kind of 'open-label' trial design could have introduced bias, potentially overestimating the effect of the drug, the researchers said.
The results of the trial were published on Friday in the JAMA Internal Medicine.
The use of ivermectin to treat Covid is currently being investigated in a UK trial run by the University of Oxford. The researchers have said they do not want to comment until they have results to report.
Buzz around ivermectin as a potential Covid treatment and prophylaxis originated from a number of studies in mid-2021 which claimed the anti-parasitic medication killed the virus in the lab.
The results were hailed by some as a major breakthrough in the pandemic as ivermectin is a cheap and widely available medication.
However, a significant number of the initial studies were found to be inherently flawed or biased, casting doubts on the drug's effectiveness.
Subsequent reviews of the drug by UK and US health authorities have concluded there is, at this time, insufficient evidence for ivermectin as a potential Covid treatment.
But this hasn't stopped people from taking the drug if they can get it.
Most recently Covid jab sceptic Laurence Fox championed its use after getting infected with the virus earlier this year.
The controversial actor turned activist posted on social media how he was taking ivermectin to treat his Covid infection after acquiring the drug while on a trip to Mexico.
Ivermectin for humans can be purchased over-the-counter in a number of countries, but not in the UK or US, where a prescription is needed.
Animal versions of the medication, for example for treating horses, can be purchased more easily.
This led to some people taking animal ivermectin, something health authorities have urged people not to do as the dosage and composition of the drug for livestock is different and can lead to potentially serious health problems.
While the jury is currently out on if the drug works as a Covid treatment UK, researchers are soon set to shine light onto the subject.
Result from a 'gold standard', double-blind, clinical trial into ivermectin effectiveness on Covid patients by the University of Oxford is expected this year.
In humans, ivermectin is used to treat a variety of conditions caused by parasites such as scabies, head lice, and round worm infections.
Ivermectin was first developed for tropical medicine. It’s commonly used to treat nasty parasitic infections, including onchocerciasis, or river blindness, which causes loss of vision and severe skin itching, and lymphatic filariasis, which causes the limb deformity elephantiasis.
It is also used in veterinarian medicine to treat similar parasitic conditions in livestock, hence it being somewhat tarred with the ‘horse dewormer’ label.
But the drug has saved numerous lives developing countries since being introduced in the late 1970s – so much so, it’s on the World Health Organisation’s list of essential medicines.
However, as the organisms that cause most of the illnesses that ivermectin treats aren’t seen in the UK, the drug isn’t as commonly used here.
No comments: